ACURA PHARMACEUTICALS, INC
LTX-03
Countdown
177days
Catalyst readout · Dec 31, 2026
What's at stake
A key catalyst for LTX-03 (its lead indication) is expected Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“This amendment #14 has an effective date of June 15, 2026 and extends the FDA’s acceptance date of a New Drug Application (“NDA”) for LTX-03 from June 30, 2026 to December 31, 2026 (“NDA Acceptance Date”) (“Amended Agreement”).”